Drug Profile


Alternative Names: QBECO SSI; Site specific immunomodulator - Qu Biologics

Latest Information Update: 05 Jan 2017

Price : $50

At a glance

  • Originator Qu Biologics
  • Class Bacterial vaccines; Cancer vaccines
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Crohn's disease; Ulcerative colitis
  • No development reported Colorectal cancer

Most Recent Events

  • 03 Mar 2017 Qu Biologics plans a follow-on phase II trial for Crohn's Disease in Canada in late 2017
  • 01 Dec 2016 Qu Biologics completes a phase II trial in Ulcerative colitis in Canada (SC) (NCT02426372)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Colorectal-cancer in Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top